Research Area COVID-19

A5407: Placebo-controlled Phase 3 Outpatient Trial of Shionogi Agent for Treatment of Symptomatic SARS-CoV-2 Infection

Open and enrolling

See locations

A5401: ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies

A master protocol to evaluate the safety and efficacy of investigational agents for the treatment of symptomatic non-hospitalized adults with…

Closed to accrual

28 days of intensive follow-up, followed by limited follow-up through 24 weeks.

See locations

A5404: SARS-CoV-2 Immune Responses after COVID-19 Therapy and Vaccine

Right now there is no medicine proven to treat COVID-19 in people who are not sick enough to be hospitalized.…

Closed to accrual

See locations